Medicines Manufacturing Industry Partnership (MMIP)

Medicines Manufacturing Industry Partnership (MMIP) is the voice of the UK medicines manufacturers.

The Medicines Manufacturing Industry Partnership (MMIP) was established in 2014 by the UK government and the biopharmaceutical industry. The partnership aims to ensure the UK’s position as a global leader in innovative advanced medicines manufacturer.

The UK medicines industry is a leading manufacturing sector, with £30 billion annual exports. The MMIP works to ensure that the UK remains an attractive place for this high-value industry, providing high-skilled jobs and contributing to the country's productivity.

The UK Life Sciences Industrial Strategy recognised the sector's high productivity, and the MMIP is now an expert group under the direction of the Life Sciences Council.

• Structure
• Workstreams

Structure

Working closely with key government organisations including the Medicines and Healthcare products Regulatory Authority (MHRA), UK Trade and Investment (UKTI), Innovate UK and the Office for Life Sciences (OLS), MMIP is continuously working to sustain the UK's leading position in medicines manufacturing technologies, including those related to advanced therapy medicinal products (ATMPs), continuous production and digitalisation.

Workstreams

MMIP is divided into five workstreams. All of these workstreams are supported by overarching communications work and building the manufacturing community to ensure it speaks with one voice.

Sarah Goulding on Community Build Medicines Manufacturing Industry Partnership (MMIP) Workstreams

These workstreams are:

• the technology and innovation landscape
• the fiscal environment
• the regulatory environment
• the skills environment
• Advanced Therapies manufacturing

---

More information on MMIP workstreams

 

MMIP also works to build the medicines manufacturing community

KTN’s Medimap provides a dynamic representation of the UK’s end-to-end medicines supply chain covering organisations involved in the discovery, development and manufacture of medicines, as well as those supporting the sector.

New report: Follow the green, high-tech road

The manufacture and supply of advanced medicines is rapidly changing, offering a huge opportunity for the UK. In this report, MMIP calls for focused action for medicines manufacturing in key areas that build on the work of recent years and accelerates progress in improving the UK’s competitive position versus other potential investment locations. 

Read the report to learn what is needed to create the right, pro-investment ecosystem for companies to choose the UK when deciding where to place their next manufacturing facility. 

Delivering the UK’s Life Sciences Manufacturing Strategy

A new report from the MMIP, ‘Delivering the UK’s Life Sciences Manufacturing Strategy’ shows that medicines and medical technology manufacturing currently deliver annual exports worth over £30 billion for the UK, on top of making a £32.1 billion (gross value added or GVA) contribution to UK economic output in 2019. This is the largest GVA contribution from the life sciences sector.

The MMIP Annual Conference 2022

The MMIP conference focused on how we can further develop the manufacturing capability of the UK over the long term to build on our strengths in Innovative R&D. It has offered a chance to discuss with senior stakeholders both from government and those in industry supporting it.

MMIP Annual Conference 2021

2021 conference reviewed the overall impact of the pandemic on the supply and manufacture of medicines for the UK, provided updates from several of the UK centres of manufacturing innovation. Watch this video with Richard Torbett, CEO of ABPI, on the importance of the MMIP conference.

Support

MMIP is supported by the ABPI, the BIA and the Knowledge Transfer Network, and includes leadership from AstraZeneca, Cell and Gene Therapy Catapult, Centre for Process Innovation, Cobra Biologics, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Innovate UK, Office for Life Sciences, Oxford Biomedica and Pfizer.